{
    "clinical_study": {
        "@rank": "107394", 
        "acronym": "PLANET", 
        "arm_group": [
            {
                "arm_group_label": "Arm A:Standard radiochemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation."
            }, 
            {
                "arm_group_label": "Arm B Escalated radiochemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the valu of individually dose escalated radiotherapy\n      compared with a standard dose of radiotherapy combined with standard concomitant\n      chemotherapy for patients with locally advanced non small cell lung cancer (stage III) with\n      good performance status."
        }, 
        "brief_title": "Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open label, multicentre phase II trial of individually escalated radiotherapy up\n      to 84 Gy due to normal tissue dose constraints combined with standard concurrent\n      chemotherapy (cisplatin-vinorelbine) compared to standard dose radiotherapy (68 Gy) combined\n      with the same chemotherapy. There are restrictions due to lung function, performance status\n      and pre-treatment weight loss. The main endpoint is progression free survival and additional\n      endpoints are local control, overall survival, toxicity quality of life and relapse pattern."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological diagnosis of NSCLC stage IIIA-B.\n\n          -  Nonresectable or medically inoperable patients.\n\n          -  No prior chemo- or radiotherapy for NSCLC.\n\n          -  PS 0-1.\n\n          -  FEV1 > 1 l or > 40% and CO diffusion capacity > 40%.\n\n          -  Patient compliance and geographic proximity that allow adequate follow-up.\n\n          -  Adequate bone marrow reserve: WBCC >3.0, platelets >100, haemoglobin > 100.\n\n          -  Written informed concent.\n\n          -  Effective use of contraception.\n\n        Exclusion Criteria:\n\n          -  Excessive weight loss within 6 months (> 10%).\n\n          -  Supraclavicular nodes.\n\n          -  Apical tumors-pancoast.\n\n          -  T4 tumors with separate manifestations in different lobes.\n\n          -  Evidence of active serious infections.\n\n          -  Inadequate liver function.\n\n          -  Inadequate kidney function.\n\n          -  Pregnancy.\n\n          -  Breast feeding.\n\n          -  Serious concomitant systemic disorder.\n\n          -  Second primary malignancy the last 5 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664663", 
            "org_study_id": "PLANET"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A:Standard radiochemotherapy", 
                "intervention_name": "Standard radiochemotherapy to 68 Gy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Arm B Escalated radiochemotherapy", 
                "intervention_name": "Dose escalated radiochemotherapy up to 84 Gy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Radiotherapy", 
            "Dose escalation", 
            "Normal tissue constraints", 
            "Locally advanced disease", 
            "Good performance status"
        ], 
        "lastchanged_date": "November 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ume\u00e5", 
                        "country": "Sweden", 
                        "state": "Norrland", 
                        "zip": "901 85"
                    }, 
                    "name": "Department of Oncology, Norrlands Universitetssjukhus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "state": "Stockholm county", 
                        "zip": "171 76"
                    }, 
                    "name": "Department of Oncology, Karolinska University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gothenburg", 
                        "country": "Sweden", 
                        "state": "V\u00e4stra G\u00f6taland", 
                        "zip": "413 45"
                    }, 
                    "name": "Department of Oncology, Sahlgrenska University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Randomized Study on Locally Advanced Non Small Cell Lung Cancer Escalated Dose on Individual Basis Treatment With Radiochemotherapy", 
        "other_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "36 months after randomization"
            }, 
            {
                "description": "According to CTC version 4.0", 
                "measure": "Numbers of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 months after randomization"
            }, 
            {
                "description": "Measured by questionaires, EORTC QLQ 30 + LC 14", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months after randomization"
            }
        ], 
        "overall_official": {
            "affiliation": "Swedish Lung Cancer Study Group", 
            "last_name": "Jan Nyman, Ass. prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "36 monts after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664663"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Swedish Lung Cancer Study Group", 
            "investigator_full_name": "Ass. Prof. Jan Nyman", 
            "investigator_title": "Assosiated professor Jan Nyman, Department of Oncology, Sahlgrenska University Hospital, Gotenburg , Sweden", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Measured with CT-scan according to the RECIST criteria for response", 
            "measure": "Numbers of patients without progression of locoregional disease", 
            "safety_issue": "No", 
            "time_frame": "36 months after randomization"
        }, 
        "source": "Swedish Lung Cancer Study Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ass. Prof. Jan Nyman", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013", 
        "why_stopped": "Safety analysis showed increased grade 5 toxicity in experimental arm."
    }
}